Author

Hanny T. Al-Samkari

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Findings support mitapivat as the first oral disease-modifying therapy for adults with transfusion-dependent α-thalassaemia or β-thalassaemia, providing a new treatment option to reduce transfusion burden in this patient population.

M. Cappellini, Sujit Sheth, A. Taher et al. · The Lancet · 3 citations

Review Oct 2026

Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration.

The emerging role of repurposed low-cost therapies, particularly hydroxyurea and thalidomide, as disease-modifying options in resource-limited settings are discussed and opportunities to democratise access to curative gene therapies through technological developments, decentralised manufacturing, regional collaboration...

Hanny T. Al-Samkari, F. Aboobacker, B. Andemariam et al. · The Lancet Haematology · 2 citations

Review Oct 2026

An evaluation of mitapivat for the treatment of non-transfusion-dependent alpha- and beta-thalassemia.

Non-transfusion-dependent thalassemia (NTDT) describes a group of inherited hemoglobin disorders characterized by hemolytic anemia and ineffective erythropoiesis. Although patients with NTDT do not require lifelong regular transfusions for survival, they are at a substantial risk of complications including iron overloa...

Aaron N. Cheng, Hanny T. Al-Samkari · Therapeutic delivery · 0 citations